Two Cases of Anti-PD1 Antibody Associated Neurological Immune-Related Adverse Effects

被引：0
|
作者：
Vitek, Grace [1 ]
Hansra, Harjot [2 ]
机构：
[1] Creighton Univ, Sch Med, Omaha, NE USA
[2] Dignity Hlth, Barrow Neurol Inst, San Francisco, CA USA
来源：
NEUROLOGY | 2023年 / 100卷 / 17期
关键词：
D O I：
10.1212/WNL.0000000000203811
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P5-4.001
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Osimertinib reactivated immune-related colitis after treatment with anti-PD1 antibody for non-small cell lung cancer
    Takenaka, Tomoyoshi
    Yamazaki, Koji
    Miura, Naoko
    Harada, Naohiko
    Takeo, Sadanori
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (06) : 848 - 850
  • [22] Osimertinib reactivated immune-related colitis after treatment with anti-PD1 antibody for non-small cell lung cancer
    Tomoyoshi Takenaka
    Koji Yamazaki
    Naoko Miura
    Naohiko Harada
    Sadanori Takeo
    Investigational New Drugs, 2017, 35 : 848 - 850
  • [23] Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases
    Garcia, Christine A.
    El-Ali, Alex
    Rath, Tanya J.
    Contis, Lydia C.
    Gorantla, Vikram
    Drappatz, Jan
    Davar, Diwakar
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [24] A CASE OF A NEUROLOGICAL IMMUNE-RELATED ADVERSE EVENT ASSOCIATED WITH IPILIMUMAB/NIVOLUMAB
    Walker, Josh
    Farag, Mena
    Josephs, Debra
    Williams, Victoria
    Holmes, Paul
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (09):
  • [25] Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes
    Lui, David Tak Wai
    Lee, Chi Ho
    Tang, Vikki
    Fong, Carol Ho Yi
    Lee, Alan Chun Hong
    Chiu, Joanne Wing Yan
    Leung, Roland Ching Yu
    Kwok, Gerry Gin Wai
    Li, Bryan Cho Wing
    Cheung, Tan To
    Woo, Yu Cho
    Lam, Karen Siu Ling
    Yau, Thomas
    ENDOCRINE PRACTICE, 2021, 27 (09) : 886 - 893
  • [26] Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
    Wang, Peng-Fei
    Chen, Yang
    Song, Si-Ying
    Wang, Ting-Jian
    Ji, Wen-Jun
    Li, Shou-Wei
    Liu, Ning
    Yan, Chang-Xiang
    FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [27] Neurological immune-related adverse events associated with immune checkpoint inhibitors: A review of the literature
    Fan, Siyuan
    Ren, Haitao
    Zhao, Luo
    Yin, Jian
    Feng, Guodong
    Wang, Jiawei
    Guan, Hongzhi
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 (06) : 291 - 298
  • [28] Immune-related adverse events: Comparison of melanoma and non-small cell lung cancer patients treated with anti-PD1 therapy
    Duma, N.
    Azzouqa, A-G.
    Yadav, S.
    Hoversten, K.
    Reed, C.
    Sitek, A. N.
    Lou, Y.
    Molina, J.
    Halfdanarson, T.
    Leventakos, K.
    Joseph, R. W.
    Manochakian, R.
    Dronca, R.
    ANNALS OF ONCOLOGY, 2018, 29 : 432 - 432
  • [29] Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody
    Matsuoka, Hiroshi
    Hayashi, Takahiro
    Takigami, Karen
    Imaizumi, Kazuyoshi
    Shiroki, Ryoichi
    Ohmiya, Naoki
    Sugiura, Kazumitsu
    Kawada, Kenji
    Sawaki, Akira
    Maeda, Koutaro
    Ando, Yousuke
    Uyama, Ichiro
    BMC CANCER, 2020, 20 (01)
  • [30] Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody
    Hiroshi Matsuoka
    Takahiro Hayashi
    Karen Takigami
    Kazuyoshi Imaizumi
    Ryoichi Shiroki
    Naoki Ohmiya
    Kazumitsu Sugiura
    Kenji Kawada
    Akira Sawaki
    Koutaro Maeda
    Yousuke Ando
    Ichiro Uyama
    BMC Cancer, 20
12345